BLU-222 — Investigational Agent

Other · Phase 1 · Blueprint Medicines

Mechanism of Action

BLU-222 is an oral, selective CDK2 inhibitor that blocks cyclin E1-CDK2 activity, targeting CCNE1-amplified and CDK4/6 inhibitor-resistant cancers.

Investigational Indications

• CCNE1-amplified HR+/HER2- breast cancer
• CCNE1-amplified ovarian and other solid tumors

Key Trials